Sun Pharma Advanced Research Company Ltd

Sun Pharma Advanced Research Company Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 01 Feb 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 March 2026, providing investors with an up-to-date view of its performance and outlook.

Sun Pharma Advanced Research Company Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 Feb 2024. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 24 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Sun Pharma Advanced Research Company Ltd (SPARC) has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. Despite some mildly bullish signals on shorter-term charts, the overall technical landscape points to increased selling pressure, reflected in the company’s recent price performance and downgraded market sentiment.

Sun Pharma Advanced Research Company Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 Feb 2024, but the analysis below reflects the stock’s current position as of 12 February 2026, incorporating the latest fundamentals, returns, and financial metrics available today.

Sun Pharma Advanced Research Company Ltd. (SPARC), the clinical-stage biopharmaceutical subsidiary of Sun Pharma, reported a net loss of ₹80.42 crores in Q3 FY26, marking yet another quarter of significant cash burn for the struggling research firm. Whilst the loss showed marginal improvement from the previous quarter's ₹75.85 crores deficit, the company's revenues continue to deteriorate sharply, plunging 43.33% year-on-year to just ₹8.45 crores. With a market capitalisation of ₹4,587 crores and negative book value, SPARC's stock trades at ₹138.30, down 32.29% from its 52-week high, reflecting mounting investor concerns about the company's viability.

Sun Pharma Advanced Research Company Ltd (SPARC) has experienced a notable shift in price momentum and technical indicators, reflecting a complex market sentiment. While some weekly and monthly indicators suggest mild bullishness, others remain bearish or neutral, signalling a cautious outlook for investors in the Pharmaceuticals & Biotechnology sector.

Sun Pharma Advanced Research Company Ltd (SPARC) demonstrated robust intraday performance on 3 Feb 2026, surging to an intraday high of Rs 148.1, marking an 11.1% increase from its previous close. The stock outperformed both its sector and the broader market, reflecting significant trading momentum amid a mixed market backdrop.

Sun Pharma Advanced Research Company Ltd (SPARC) commenced trading on 3 Feb 2026 with a significant gap up, opening 7.99% higher than its previous close. This robust start reflects positive market sentiment within the Pharmaceuticals & Biotechnology sector, as the stock outperformed both its sector peers and the broader Sensex index during the day.

Sun Pharma Advanced Research Company Ltd (SPARC) has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. Despite a modest intraday volatility, the stock’s technical parameters suggest increasing downside risks, reflecting broader challenges in the Pharmaceuticals & Biotechnology sector.

Sun Pharma Advanced Research Company Ltd (SPARC) has experienced a notable shift in price momentum, reflected in a complex interplay of technical indicators. Despite a strong intraday rally pushing the stock to ₹141.95, the broader technical landscape remains cautiously bearish, with key momentum oscillators and moving averages signalling a nuanced outlook for investors.

Sun Pharma Advanced Research Company Ltd recorded a robust intraday performance on 1 Feb 2026, surging 10.81% to touch a day’s high of Rs 135, significantly outperforming the broader Sensex and its sector peers in Pharmaceuticals & Biotechnology.

Sun Pharma Advanced Research Company Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 February 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 01 February 2026, providing investors with the latest data to understand the rationale behind this recommendation.

Sun Pharma Advanced Research Company Ltd (SPARC) has experienced a marked deterioration in its technical outlook, with key momentum indicators signalling a shift towards a more pronounced bearish trend. The stock’s recent price action, combined with weakening moving averages and negative MACD readings, underscores growing investor caution amid broader sector challenges.

Sun Pharma Advanced Research Company Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 Feb 2024, reflecting a significant reassessment of the stock’s outlook. However, the analysis and financial metrics presented here are based on the company’s current position as of 21 January 2026, providing investors with the latest insights into its performance and prospects.

Sun Pharma Advanced Research Company Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 01 Feb 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 January 2026, providing investors with the latest insights into the company’s performance and outlook.

Sun Pharma Advanced Research Company Ltd (SPARC) has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish indicators. Despite a modest daily price increase, the stock remains under pressure over longer time horizons, with technical parameters signalling a transition from bearish to mildly bearish trends.